Company profile

Lantheus Holdings, Inc.

NASDAQ:LNTHBiotechnology: In Vitro & In Vivo Diagnostic Substances

Drug pipeline (8)

AssetStageRevenueTrialsStatus
FLORBETABEN F-18approved1approved
FLORQUINITAU F-18approved0
GADOFOSVESET TRISODIUMapproved0
GALLIUM CITRATE GA-67approved0
PERFLUTRENapproved4approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (40)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00891241phase1completed2009-08-012009-11-01Lantheus Medical ImagingA Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure
NCT01347710phase3completed2011-06-012013-07-01Lantheus Medical ImagingA Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD.
NCT00707538phase1completed2008-06-012008-10-01Lantheus Medical ImagingA Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress
NCT00707499phase1completed2007-09-012008-05-01Lantheus Medical ImagingA Phase I Study in Healthy Volunteers to Assess Safety of BMS747158
NCT00162058phase2completed2004-03-012006-04-01Lantheus Medical ImagingA Phase II Study of DMP 115 to Assess Focal Liver Lesions

FDA applications (9)

ApplicationTypeApplicantProducts
ANDA 217060ANDALANTHEUS MEDICAL IMAGING INC
NDA 017283NDALANTHEUS MEDICAL IMAGING INC
NDA 017478NDALANTHEUS MEDICAL IMAGING INC
NDA 017806NDALANTHEUS MEDICAL IMAGING INC
NDA 020570NDALANTHEUS MEDICAL IMAGING INC